43 subjects (ages 13–38), one-third of whom were between 13 and 17 years old, with skin phototypes I through III. 100% of the panel experienced treatment-related discomfort, erythema, dryness, and scaling.  

Twenty-one subjects were treated with oral isotretinoin, and 22 subjects were treated with a topical regimen (BPO, retinoid, or adapalene + BPO).  

Tolerance Assessment: 

• Dermatological  
• Ophthalmological  

Efficacy assessment:  

• Clinical scoring of functional and physical signs (scales from 0 to 4) 
• Clinical scoring of changes in discomfort (scale from 0 to 10) 
• Changes in post-inflammatory marks (scale from 0 to 11)  

• Good skin tolerance and very good eye tolerance  
• Half as many functional symptoms after the first application  

• -60% reduction in post-inflammatory marks (PIE and PIH) in 1 month 

Immediate and long-term effectiveness for:

• Physical signs: 

-88% reduction in dryness after 1 month of use

-92% reduction in flaking after 1 month of use

• Functional signs: 

-57% after the first use

-94% after 1 month of use 

With good skin tolerance and excellent eye tolerance, CLEANANCE HYDRA cream helps counteract the harmful effects of drying treatments on the skin and reduce post-inflammatory marks in as little as one month.